Objective: To explore the application value of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) specimens combined with DNA methylation detection in the clinical diagnosis of lung cancer, compare the diagnostic efficacy of single detection methods, and provide objective evidence for early and accurate diagnosis of lung cancer. Methods: A total of 120 patients with suspected pulmonary malignancies admitted to our hospital from December 2024 to December 2025 were selected. All patients underwent EBUS-TBNA to obtain biopsy specimens, and routine pathological cytological examination, individual detection of SHOX2 and RASSF1A gene methylation, and combined detection of both methods were performed. Using postoperative pathology or long-term follow-up results as the gold standard, the sensitivity, specificity, accuracy, positive predictive value, negative predictive value, and area under the ROC curve (AUC) of each detection method were calculated, and diagnostic differences were compared. Results: Among the 120 patients, 76 cases (63.33%) were diagnosed with lung cancer and 44 cases (36.67%) with benign lesions according to the gold standard. The sensitivity, specificity, and accuracy of routine cytological examination by EBUS-TBNA were 72.37%, 84.09%, and 76.67%, respectively; for individual DNA methylation detection, they were 78.95%, 86.36%, and 81.67%, respectively; for combined detection, they were 93.42%, 95.45%, and 94.17%, respectively. All diagnostic indicators of combined detection were significantly superior to those of single detection methods (P < 0.05). The area under the ROC curve for combined detection was 0.980, significantly higher than that for individual cytological detection (0.908) and individual methylation detection (0.934). Conclusion: EBUS-TBNA specimens combined with DNA methylation detection can significantly improve the sensitivity and accuracy of lung cancer diagnosis, overcome the limitations of routine cytological examination, and are particularly suitable for difficult cases such as mediastinal lymphadenopathy and peripheral pulmonary nodules, demonstrating high clinical promotion value.
Fan H, Deng S, Wang L, et al., 2025, Nrf2 Serves as a Biomarker and Therapeutic Target in Lung Cancer Based on Bibliometric Analysis and Molecular Mechanisms. Discover Oncology, 17(1): 171.
Yang Y, Zhang Z, Liu P, et al., 2026, The Application Value of Endobronchial Ultrasound-Guided Transbronchial Mediastinal Cryobiopsy in the Diagnosis of Pulmonary Sarcoidosis: A Retrospective Comparative Study with Needle Aspiration Biopsy. Journal of Xuzhou Medical University, 46(1): 57–61.
Ruan H, Wu D, Zhu C, et al., 2026, Detection of SHOX2 and RASSF1A Gene Methylation Assists in the Early Diagnosis of Lung Cancer in Three Cases. Chinese Journal of Clinical Laboratory Science, 44(1): 64–66.
Cao R, Wang B, Lai X, et al., 2025, Correlation Study Between Traditional Chinese Medicine Susceptibility Constitution of Small Pulmonary Nodules and Methylation of SHOX2/RASSF1A/PTGER4 Genes. Chinese Journal of Information on Traditional Chinese Medicine, 32(8): 146–152.
Cen L, Sui B, 2025, Research Progress of Fiberoptic Bronchoscopy in the Diagnosis, Staging, and Treatment of Lung Cancer. Chinese Journal of Medical Physics, 42(11): 1500–1506.
Pan D, Ying J, Wu Q, et al., 2019, Comparative Application of Conventional Exfoliative Cytology and Liquid-Based Cytology with Bronchial Brushings in the Pathological Diagnosis of Lung Cancer. Zhejiang Practical Medicine, 24(2): 86–89.
Qi Q, Su H, Hu J, et al., 2025, Diagnostic Value of Serum SHOX2, RASSF1A, and PTGER4 Methylation Levels for Benign and Malignant Solitary Pulmonary Nodules and Pathological Classification. Journal of Diagnostic Pathology, 32(8): 1010–1015.
Wang M, Mukandais T, Nurziba A, et al., 2024, Predictive Value of a Nomogram Model Constructed by Combining SHOX2, RASSF1A, and CEA for the Occurrence of Lung Cancer. Journal of Xinjiang Medical University, 47(7): 996–1000 + 1007.
Liu Y, 2023, DNA Methylation Testing Aids in Early Tumor Screening and Diagnosis. Theory and Practice of Diagnostics, 22(4): 393–401.
He S, Tian J, Long L, et al., 2024, Lung Cancer Screening and Early Diagnosis: Progress from Imaging to Biomarkers. Chinese Journal of Cancer Prevention and Treatment, 16(1): 120–126.